International audienceTMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its expression is frequently associated with poor prognosis. Our aim is to achieve gene knockdown by siRNA TMPRSS2-ERG and then to assess the biological consequences of this inhibition. First, we designed siRNAs against the two TMPRSS2-ERG fusion variants (III and IV), most frequently identified in patients' biopsies. Two of the five siRNAs tested were found to efficiently inhibit mRNA of both TMPRSS2-ERG variants and to decrease ERG protein expression. Microarray analysis further confirmed ERG inhibition by both siRNAs TMPRSS2-ERG and revealed one common down-regulated gene, ADRA2A, involved in cell proliferation and migrati...
Many aspects of the mechanisms by which prostate cancer (PCa) progresses from being a confined tumou...
Prostate cancer is one of the leading causes of cancer-related death in men worldwide. If diagnosed ...
Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxi...
International audienceTMPRSS2-ERG junction oncogene is present in more than 50% of patients with pro...
TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its e...
Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa)...
Short interfering RNAs (siRNAs) have provided novel insights into the field of cancer treatment in l...
Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treat...
BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is ...
Cilj ovog rada je bio pronaći prikladnu terapiju za rak prostate kombinacijom dva različita pristupa...
The transmembrane protease serine 2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) ...
Chromosomal translocations that juxtapose the androgen-sensitive TMPRSS2 gene promoter to the oncoge...
BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is ...
Gene therapy is a potent and versatile nano-medicine strategy in the treatment of cancer. Of the man...
Simultaneous silencing of multiple apoptosis-related genes is an attractive approach to treat cancer...
Many aspects of the mechanisms by which prostate cancer (PCa) progresses from being a confined tumou...
Prostate cancer is one of the leading causes of cancer-related death in men worldwide. If diagnosed ...
Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxi...
International audienceTMPRSS2-ERG junction oncogene is present in more than 50% of patients with pro...
TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its e...
Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa)...
Short interfering RNAs (siRNAs) have provided novel insights into the field of cancer treatment in l...
Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treat...
BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is ...
Cilj ovog rada je bio pronaći prikladnu terapiju za rak prostate kombinacijom dva različita pristupa...
The transmembrane protease serine 2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) ...
Chromosomal translocations that juxtapose the androgen-sensitive TMPRSS2 gene promoter to the oncoge...
BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is ...
Gene therapy is a potent and versatile nano-medicine strategy in the treatment of cancer. Of the man...
Simultaneous silencing of multiple apoptosis-related genes is an attractive approach to treat cancer...
Many aspects of the mechanisms by which prostate cancer (PCa) progresses from being a confined tumou...
Prostate cancer is one of the leading causes of cancer-related death in men worldwide. If diagnosed ...
Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxi...